1,608 results on '"Andreeff, M."'
Search Results
2. Correction to: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia
3. Measurement of relative lung perfusion with electrical impedance and positron emission tomography: an experimental comparative study in pigs
4. Results of MDR-1 Vector Modification Trial Indicate that Granulocyte/Macrophage Colony-Forming Unit Cells Do not Contribute to Posttransplant Hematopoietic Recovery Following Intensive Systemic Therapy
5. Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin.
6. Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
7. The Participation of Mesenchymal Stem Cells in Tumor Stroma Formation and Their Application as Targeted-Gene Delivery Vehicles
8. P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA
9. S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
10. P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA
11. P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA
12. Leukemia Stem Cells with Efficient Drug Efflux in Acute Myeloid Leukemia
13. Quantitative Determination of Bcl-2 Expression in AML Cell Lines and in Normal and Leukemic Progenitor Cell Compartments by Laser Scanning Cytometry: Comparison with Flow Cytometry and Western Blot
14. Reduced Level of Philadelphia Chromosome Positive (Ph+) Cells in Lineage Negative Side Population Bone Marrow Progenitor Cells from Patients with Chronic Myeloid Leukemia (CML)
15. Cytokinetic Resistance in Acute Leukemia: Recombinant Human Granulocyte Colony-Stimulating Factor, Granulocyte Macrophage Colony-Stimulating Factor, Interleukin-3 and Stem Cell Factor Effects In Vitro and Clinical Trials with Granulocyte Macrophage Colony-Stimulating Factor
16. Treatment Planning and Dose Verification for Combined Internal and External Radiotherapy (CIERT)
17. The Usage Of Gated SPECT in Lung Scintigraphy Phantom Studies and Clinical Results
18. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation
19. GD3 synthase regulates epithelial–mesenchymal transition and metastasis in breast cancer
20. Recent Studies in AML, RAEB-t, and RAEB at M.D. Anderson Hospital
21. FLAG-Ida, an Effective Regimen for High Risk AML
22. Liposomal Delivery of P-Ethoxy Antisense Oligodeoxynucleotides in Chronic Myelogenous Leukemia
23. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML
24. Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside
25. Importance of Long-Term Follow-up in Evaluating Treatment Regimens for Adults with Acute Lymphoblastic Leukemia
26. Recruitment Therapy in Acute Myeloblastic Leukemia:A Different Approach to Improved Leukemia Treatment
27. Prognostic Factor Analyses in Acute Myeloid Leukemia: M.D. Anderson Experience
28. RNA Content in Human Lymphocyte Subpopulations
29. Detection of bcr-abl Fusion in Chronic Myelogeneous Leukemia by in Situ Hybridization
30. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML
31. In reply to the Letter to the Editor by Chen and Lui regarding 'Radiotherapy enhances uptake and efficacy of 90 Y-cetuximab: A preclinical trial' by A Dietrich et al
32. Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial
33. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor
34. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts
35. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors
36. RETRACTED ARTICLE: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
37. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML
38. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways
39. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
40. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients
41. A semi-automated system for concentration of rhenium-188 for radiopharmaceutical applications
42. The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe
43. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells
44. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells
45. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis
46. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells
47. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma
48. HOX expression patterns identify a common signature for favorable AML
49. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
50. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.